Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis
CXCR2 antagonism has been shown to be anti-arthritic, but anti-chemokine therapies usually fail in the clinic owing to redundancy in chemokine-receptor interactions. Here the authors develop single-chain antibodies with multiple chemokine specificities to achieve high affinity and broad specificity...
Main Authors: | Alessandro Angelini, Yoshishige Miyabe, Daniel Newsted, Byron H. Kwan, Chie Miyabe, Ryan L. Kelly, Misha N. Jamy, Andrew D. Luster, K. Dane Wittrup |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2018-04-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-03687-x |
Similar Items
-
Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis
by: Miyabe, Yoshishige, et al.
Published: (2018) -
Chemokines and chemokine receptors as promising targets in rheumatoid arthritis
by: Masanori A. Murayama, et al.
Published: (2023-02-01) -
Streptococcal infection and autoimmune diseases
by: Ayaka Ohashi, et al.
Published: (2024-02-01) -
Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis
by: Chie Miyabe, et al.
Published: (2021-10-01) -
Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis.
by: Marzia Dolcino, et al.
Published: (2014-01-01)